KK 2845
Alternative Names: KK-2845Latest Information Update: 10 Dec 2024
Price :
$50 *
At a glance
- Originator Kyowa Kirin
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Antibody-dependent cell cytotoxicity; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
Most Recent Events
- 10 Oct 2024 Phase-I clinical trials in Acute myeloid leukaemia in Japan (IV) (jRCT2011240008)
- 30 Jun 2024 Preclinical trials in Acute myeloid leukaemia in Japan (Parenteral) before June 2024 (Kyowa Kirin pipeline, August 2024)
- 30 Jun 2024 Kyowa Kirin plans a phase I trial for Acute myeloid leukemia in Japan (Kyowa Kirin pipeline, August 2024)